SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is seeing renewed community activity driven by speculative optimism and discussions about a potential price breakout, with investors debating the asset's long-term utility against its meme coin roots. Supporters remain focused on accumulation and burning strategies, while others express caution regarding historical performance and the volatility inherent in the meme coin sector.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is rallying behind the project with intense conviction, emphasizing long-term 'bagworking' and the creation of OG-style rage comics to drive mindshare. Investors are actively pushing to secure a top market position while warning against copycat tickers and urging others to join their grassroots effort before a potential breakout.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Crypto token is actively being labeled by the community as a major pump-and-dump scheme, with discussions centering on the massive losses sustained by retail investors compared to the significant profits reportedly realized by insiders and organizers. Many users are using the symbol as a venue to vent political frustrations and share concerns about the perceived grifting tactics associated with the Trump family's various crypto and media ventures.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following the publication of positive Phase 3 VIKTORIA-1 trial data, which demonstrated significant survival benefits for its investigational breast cancer drug, gedatolisib. Investors are actively discussing the potential for an accelerated FDA approval timeline, the strategic implications of a recent capital raise, and the stock's long-term value as a potential first-in-class standard of care.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending as investors closely monitor its role in the AI-driven data center and optical packaging sector, with community sentiment divided between excitement over long-term growth and caution regarding valuation and potential supply chain shifts. Discussion is heavily focused on the company's recent earnings performance, its strategic importance as a manufacturer for major tech partners, and its ability to sustain momentum amid sector volatility.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is gaining institutional momentum ahead of its upcoming earnings as investors rotate out of technology and into resilient healthcare names, while the company leverages a robust portfolio of mature drugs and late-stage pipeline assets to navigate competitive pricing pressures. Market participants are closely watching the company's capital allocation strategy and manufacturing expansion efforts, which are being bolstered by favorable policy developments and a strengthening competitive position in the cardiovascular and inflammatory disease markets.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor attention due to speculation regarding its short-squeeze potential and optimism surrounding its strategic AI partnerships. Community discussions are heavily focused on the stock's low float and aggressive roadmap, leading to polarized debates over whether the momentum represents a long-term growth opportunity or a volatile trading setup.

CoreCivic, Inc. operates as a government solutions company, which engages in the development and management of prisons and other correctional facilities. It operates through the following segments: Safety, Community, and Properties. The Safety segment consists of correctional and detention facilities. It provides transportation services to government agencies and TransCoR. The Community segment offers residential reentry centers and provides electronic monitoring case management services. The Properties segment consists of real estate properties owned by the company that are leased to government agencies. The company was founded by Thomas W. Beasley, T. Don Hutto, and Robert Crants on January 28, 1983 and is headquartered in Brentwood, TN.

CoreCivic Inc

CoreCivic is trending as investors weigh potential shifts in detention policy and government contracting against recent reports of ICE scaling back its reliance on private detention facilities in favor of government-owned sites. While some community members are bullish on the company's long-term valuation and balance sheet, others are actively discussing the ethical and operational risks surrounding private detention, including ongoing litigation and regulatory pressures.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Puma Biotechnology is seeing heightened investor activity and volatility as the community closely monitors a critical jury trial against AstraZeneca regarding patent infringement, which remains a primary driver for the stock's outlook. Investors are weighing the impact of ongoing legal developments and recent pipeline trial data against the company's financial performance, while some traders actively debate the potential for a buyout versus the necessity of aggressive cost-cutting measures.

Bob’s Discount Furniture, Inc. is a holding company, which engages in the retail of home furnishings. The firm's products include reclining sofa, table lamp, storage ottoman, top coffee and end table set, rug, storage television stand, and swivel chair. Its store locations include New England, New York, Mid Atlantic, Midwest, and West. The company was founded by Robert Kaufman in 1991 and is headquartered in Manchester, CT.

Bob`s Discount Furniture Inc.

Bob's Discount Furniture is generating intense debate following its recent market debut, with investors weighing concerns over selling pressure and IPO timing against the company's brand recognition as a value-focused retailer. The community remains divided, with technical analysts tracking consolidation patterns while others express skepticism regarding long-term business quality and exposure to tariff risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royal Bank Of Canada Initiates Coverage on Pharvaris (NASDAQ:PHVS)

Royal Bank Of Canada began coverage on shares of Pharvaris in a report on Monday. They issued an "outperform" rating and a $52.00 price objective for the company...

HC Wainwright Reaffirms "Buy" Rating for Pharvaris (NASDAQ:PHVS)

HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday...

Pharvaris (NASDAQ:PHVS) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered shares of Pharvaris from a "hold" rating to a "sell" rating in a research note on Saturday...

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the firm, Marketbeat reports. One...

Wall Street Zen downgraded Pharvaris from a "hold" rating to a "sell" rating in a research note on Saturday...

Pharvaris (NASDAQ:PHVS) Shares Down 5.7% - What's Next?

Pharvaris (NASDAQ:PHVS) Shares Down 5.7% - Time to Sell...

Pharvaris (NASDAQ:PHVS) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Pharvaris from a "sell" rating to a "hold" rating in a research note on Saturday...

Pharvaris (NASDAQ:PHVS) Shares Up 3.8% - Should You Buy?

Pharvaris (NASDAQ:PHVS) Shares Up 3.8% - Here's Why...

Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 636,914 shares, an increase of...

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve research firms that are covering the company, MarketBeat reports. One...

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

PHVS
Pharvaris NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHVS News

PHVSPharvaris NV